Table 1 Baseline patient characteristics
| Â | Dopamine infusion | p-value | |
|---|---|---|---|
|  | No (n = 250) | Yes (n = 44) | |
Demographic data | |||
 Age (years) | 70.8 (9.6) | 72.4 (9.5) | 0.319 |
 Female | 46 (18.4%) | 7 (15.9%) | 0.854 |
Body mass index (kg/m2) | 0.335 | ||
  < 18.5 kg/m2 | 17 (6.8%) | 3 (6.8%) |  |
 18.5–24.9 kg/m2 | 145 (58.0%) | 30 (68.2%) |  |
 25.0–29.9 kg/m2 | 74 (29.6%) | 11 (25.0%) |  |
  ≥ 30.0 kg/m2 | 14 (5.6%) | 0 (0.0%) |  |
Past medical history | |||
 Hypertension | 169 (67.6%) | 28 (63.6%) | 0.733 |
 Diabetes mellitus | 35 (14.0%) | 6 (13.6%) | 1.000 |
 Dyslipidemia | 81 (32.4%) | 13 (29.5%) | 0.842 |
 Cerebrovascular disease | 18 (7.2%) | 2 (4.5%) | 0.749 |
 Angina pectoris | 48 (19.2%) | 7 (15.9%) | 0.759 |
 Myocardial infarction | 17 (6.8%) | 5 (11.4%) | 0.453 |
 Atrial fibrillation | 8 (3.2%) | 1 (2.3%) | 1.000 |
 Chronic obstructive lung disease | 18 (7.2%) | 4 (9.1%) | 0.897 |
Medication history | |||
 Aspirin | 57 (22.8%) | 8 (18.2%) | 0.629 |
 Clopidogrel | 43 (17.2%) | 5 (11.4%) | 0.456 |
 ACEi/ARB | 93 (37.2%) | 11 (25.0%) | 0.165 |
 ß blocker | 66 (26.4%) | 14 (31.8%) | 0.575 |
 Calcium channel blocker | 91 (36.4%) | 19 (43.2%) | 0.491 |
 Diuretics | 36 (14.4%) | 6 (13.6%) | 1.000 |
 Statin | 111 (44.4%) | 15 (34.1%) | 0.267 |
 Oral hypoglycemic agents | 26 (10.4%) | 4 (9.1%) | 1.000 |